Published in J Clin Oncol on May 15, 2004
Gefitinib has the potential of activating cell immunity against malignant cells. J Clin Oncol (2005) 0.77
Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma. Cancer Res Treat (2005) 0.75
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Role of HER2 in wound-induced breast carcinoma proliferation. Lancet (2003) 3.40
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets (2012) 2.55
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol (2005) 2.36
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2009) 2.30
Biologic and therapeutic role of HER2 in cancer. Oncogene (2003) 2.26
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist (2006) 1.80
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
Leptin signaling in breast cancer: an overview. J Cell Biochem (2008) 1.71
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol (2004) 1.69
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics (2010) 1.68
Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene (2005) 1.60
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery? Eur J Cardiothorac Surg (2011) 1.57
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist (2009) 1.53
Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol (2002) 1.53
Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. J Clin Oncol (2005) 1.49
Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One (2011) 1.48
Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol (2012) 1.45
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol (2012) 1.43
Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biol Ther (2011) 1.42
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol (2006) 1.37
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol (2011) 1.32
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One (2013) 1.32
A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res (2003) 1.32
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest (2003) 1.27
Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol (2005) 1.26
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer (2009) 1.24
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol (2004) 1.24
Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene (2005) 1.22
Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res (2006) 1.18
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol (2005) 1.16
Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst (2005) 1.10
Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem (2012) 1.10
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2015) 1.10
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.10
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer (2010) 1.06
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat (2009) 1.06
Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol (2002) 1.04
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget (2013) 1.03
EGFR-targeted therapy. Exp Cell Res (2011) 1.03
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev (2012) 1.01
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res (2002) 1.00
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol (2008) 0.99
Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol (2008) 0.99
Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. J Cell Sci (2005) 0.99
HER2 as a target for breast cancer therapy. Expert Opin Biol Ther (2010) 0.99
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer (2012) 0.99
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev (2012) 0.98
Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol (2002) 0.98
A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. Hum Pathol (2011) 0.98
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol (2003) 0.97
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer (2007) 0.97
Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer (2010) 0.96
Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol (2006) 0.96
Quality of Life in elderly patients with cancer. Health Qual Life Outcomes (2003) 0.95
FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci U S A (2006) 0.95
Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol (2005) 0.95
Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer (2009) 0.95
Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. Int J Oncol (2011) 0.95
Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med (2013) 0.94